We seek greater understanding of the genetic and epigenetic mechanisms driving tumorigenesis and disease progression in malignant brain tumors. We currently study the capacity of cellular and cell-free DNA to inform treatment choices in patients with brain tumors. We also use single cell and cell subtype-specific transcriptomics to identify and target infiltrating glioblastoma. We hope to identify potentially targetable genes crucial in tumorigenesis. Our laboratory is a unique and collaborative working environment, engaged in a dynamic research environment at Stanford. Our laboratory space lies at the heart of the Stanford campus between the core campus and the medical facilities, emblematic of the translational aspects of our work.
Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse.
Neuron | January 2016 | Volume 89, Issue 1, 6 | Pages 37–53
The functional and molecular similarities and distinctions between human and murine astrocytes are poorly understood. Here, we report the development of an immunopanning method to acutely purify astrocytes from fetal, juvenile, and adult human brains and to maintain these cells in serum-free cultures.
Read more at:
A survey of human brain transcriptome diversity at the single cell level.
PNAS | June 9, 2015 | vol. 112 | no. 23 | 7285–7290
The human brain is a tissue of vast complexity in terms of the cell types it comprises. Conventional approaches to classifying cell types in the human brain at single cell resolution have been limited to exploring relatively few markers and therefore have provided a limited molecular characterization of any given cell type. We used single cell RNA sequencing on 466 cells to capture the cellular complexity of the adult and fetal human brain at a whole transcriptome level.
Read more at:
New tools for studying microglia in the mouse and human CNS.
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12)
Here, we identify transmembrane protein 119 (Tmem119), a cell-surface protein of unknown function, as a highly expressed microglia-specific marker in both mouse and human. We developed monoclonal antibodies to its intracellular and extracellular domains that enable the immunostaining and isolation of microglia. Using our antibodies, we provide, to our knowledge, the first RNAseq profiles of highly pure mouse microglia during development and after an immune challenge.
Read more at:
Brain tumor mutations detected in cerebral spinal fluid.
Clin Chem. 2015 Mar;61(3):514-22.
In this study, tumor mutations were detectable in cfDNA from the CSF of patients with different primary and metastatic brain tumors. We designed two liquid biopsy strategies to characterize tumor mutations in CSF for potential clinical diagnosis: the targeted detection of known driver mutations to monitor brain metastasis and the global characterization of genomic aberrations to direct personalized cancer care.
Read more at:
The "Liquid Biopsy": the Role of Circulating DNA and RNA in Central Nervous System Tumors.
Curr Neurol Neurosci Rep. 2016 Mar;16(3):25.
The detection of tumor-derived circulating nucleic acids in patients with cancer, known as the "liquid biopsy," has expanded from use in plasma to other bodily fluids in an increasing number of malignancies. Recent work suggests that cerebrospinal fluid may be a useful source of CNS tumor-derived circulating nucleic acids. In this review, we discuss the available data and future outlook on the use of the liquid biopsy for CNS tumors.
Read more at:
Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases.
J Neurooncol. 2016 May;128(1):93-100.
In this report, we used droplet digital PCR to test mutant tumor DNA in CSF of a patient to monitor the treatment response of metastatic melanoma leptomeningeal disease (LMD). The mutant DNA fraction in CSF corresponded well with the patient's clinical response. We used whole exome sequencing to examine the mutation profiles of the LMD tumor DNA in CSF before therapeutic response and after disease relapse. The cellular and cfDNA revealed similar mutation profiles, suggesting cfDNA is representative of LMD cells.
Read more at:
Linya, Lina, Candace, Ian, Sophia, Eli, Yingmei, Melanie
(from left to right)
Our team combines experience with passion, creativity, and dedication.
Melanie Hayden Gephart
Dr. Hayden did her residency at Stanford University in neurosurgery and joined as faculty in 2014. She worked previously in Matthew Scott's lab studying medulloblastoma in a mouse model.
Yingmei obtained her PhD in chemistry from Purdue University in 2014. Her PhD work focused on DNA/RNA nanotechnology. She has been working on liquid biopsy of metastatic and primary brain tumors since she joined our lab. She enjoys movies, hiking and tiramisu!
Sophia is an experienced cancer biologist with a background in cell and molecular biology, protein biochemistry, assay development, biomarker discovery and drug development.
Dina obtained her PhD in pharmacology from Tel Aviv University. She has an extensive background in development and in vitro / in vivo characterization of polymer-based nanomedicines for the treatment of solid tumors.
Ian is a medical student interested in neurosurgery. He completed his undergraduate and graduate degrees in mechanical engineering at Stanford where he also played on the men's volleyball team.
Eli is a medical student at Stanford interested in neurosurgery. He completed his bachelors degree at NYU
where he also competed on the track and field team.
Lina is an undergraduate at Stanford. She is a Human Biology major and is contemplating applying to medical school.
Neuro-oncology research, it's personal
Neurosurgery isn't just my career and practice, it is a personal struggle to help improve the treatment for patients with brain tumors. These diseases have taken the lives of many of my friends and family, and affects the lives of my patients every day. Just a handful of their photos are listed here. We are committed to improving the care of patients with brain tumors and understanding the underlying mechanisms of disease progression, motivated by a personal understanding of the disease. I work in the operating room employing the maximal treatment for patients in my clinic today. The lab looks to develop new treatments and diagnostic techniques for the future patients who will be in the clinic tomorrow.
Robert Bean (1966 - 2000)
Robert Bean, Dr. Hayden's uncle, passed away at the age of 37 from Glioblastoma.
Paul Kalanithi (1977 - 2015)
Paul, Dr. Hayden's co-resident, was diagnosed with metastatic lung cancer during his neurosurgery residency. He passed away at the age of 37.
Position: Graduate Student
Years in lab: 2013 - 2016
Current position: Scientist at Grail Inc.
Position: Post doctorate
Years in lab: 2015 - 2016
Current position: Shanghai Medical College of Fudan University
SUPPORT OUR RESEARCH
Please follow the link below and fill out the fields as indicated above. We greatly appreciate your support.
Interested in joining our team?
Please submit a CV with a brief description of your research interests and career goals to Melanie Hayden Gephart (email@example.com)
We are looking for a postdoctoral or early research scientist to accelerate the study and targeting of ifiltrating glioblastoma using refined methods with primary human brain and brain tumor samples. A competitive applicant for this position will have an interest in glioblastoma, glial biology, and working with patient-derived samples. Candidates must hold a Ph.D. from an accredited institution in a relevant research field, have strong laboratory, analytical, and organizational skills, and be able to work independently, as well as part of a team. Our work in the laboratory will enhance patient care through an improved understanding of malignant brain tumor biology.